ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,812.55
-0.20%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.645
-0.02%
Brent Oil
83.76
0.00%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) ニュース

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CADL
日付受信時刻ニュースソース見出しコード企業名
2024/05/1421 : 30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
2024/05/1421 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2024/05/1421 : 00GlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
2024/04/2521 : 00GlobeNewswire Inc.Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
2024/04/1122 : 00GlobeNewswire Inc.Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
2024/04/0921 : 00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsNASDAQ:CADLCandel Therapeutics Inc
2024/04/0421 : 00GlobeNewswire Inc.Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
2024/03/2905 : 05GlobeNewswire Inc.Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
2024/03/2821 : 05GlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
2024/03/0622 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2024/03/0606 : 30GlobeNewswire Inc.Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateNASDAQ:CADLCandel Therapeutics Inc
2024/02/1323 : 00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
2024/02/1321 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2024/02/1321 : 30GlobeNewswire Inc.CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
2024/02/0522 : 00GlobeNewswire Inc.Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsNASDAQ:CADLCandel Therapeutics Inc
2024/01/1922 : 30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2024/01/1306 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2024/01/0322 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2023/12/1222 : 58Dow Jones NewsCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409NASDAQ:CADLCandel Therapeutics Inc
2023/12/1222 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2023/12/1222 : 00GlobeNewswire Inc.Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
2023/12/0107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2023/12/0107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2023/12/0107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2023/11/2906 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2023/11/2906 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2023/11/2906 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
2023/11/2823 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
2023/11/2823 : 00GlobeNewswire Inc.Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409NASDAQ:CADLCandel Therapeutics Inc
2023/11/2207 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CADL

最近閲覧した銘柄

LATK
RALLYUSDT
Rally Coin
NASDAQ
CSSEN
Chicken Soup for the Sou...
COIN
BIRDSUSD
COIN
CHIPUSD
BIT
F34606
Vontobel Financial Produ...
BIT
F34790
Vontobel Financial Produ...
BIT
F34522
Vontobel Financial Produ...
ASX
LT7HB
La Trobe Capital Markets...
BIT
P1J459
BNP Paribas Issuance
BIT
F36298
Vontobel Financial Produ...
BIT
F37018
Vontobel Financial Produ...
BIT
F14976
Vontobel Financial Produ...
USOTC
AVVZF
Avanza Bank Holding AB (PK)
BOV
INGG34R
ING Groep N.V
AMEX
SATX
SatixFy Communications
BIT
P1R684
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有